trk-950
Generic: Anti-Caprin-1 Monoclonal Antibody TRK-950·Code: TRK-950
trk-950: 1 clinical trial tracked.
trk-950 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about trk-950, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors
Primary endpoint: Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0
Interventionalopen138 targetStarted 2019-04Completion 2026-0614 sites · France, United StatesToray Industries, Inc